Promising Phase III Data For Roche/Ipsen's Taspoglutide Heats Up GLP-1 Race
This article was originally published in The Pink Sheet Daily
Executive Summary
Once-weekly human GLP-1 analog taspoglutide shows superior HbA1c reduction to Byetta - and may soon catch Novo's liraglutide.
You may also be interested in...
Lilly Stands By Experimental Diabetes Drug, Despite Questions About Data
Recent data showing faster heart and blood pressure rates lead some analysts to question the drug maker's strategy for its diabetes drug.
Novo Disappoints With No Liraglutide News, But Growth Is Strong
Novo delivered strong first-half results, but provided little further clarity on liraglutide's progress at FDA.
Radiopharmaceuticals: A New Frontier In Precision Cancer Therapy
Growing interest in radioligand-based cancer therapies reflects the class’s unique advantages – including the ability to “see what you treat.”